Eleven (11) out of 16 MS patients were currently medicated with a disease-modifying therapy, of which five took glatiramer acetate, three dimethyl fumurate and one each fingolimod, natalizumab or interferon beta. This evidence concerns the gene IFNB1 and myeloid sarcoma.